BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
With a call of 130 decibels, the bare-throated bellbird is a big-beaked marvel.
Autonomous blood-drawing devices could help address phlebotomist shortages.